Innovative Medicines Initiative

IMI2 to launch in January 2014

Wednesday, July 17, 2013 01:07 PM

The European Innovative Medicines Initiative 2 (IMI2) is a Joint Technology Initiative (JTI) bringing together companies, universities, public laboratories, innovative SMEs, patient groups and regulators. It will pave the way for breakthrough vaccines, medicines and treatments to address Europe’s health challenges through a combined science and innovation effort.

More... »

New IMI projects to revitalize antibiotic development

Wednesday, February 13, 2013 02:04 PM

The Innovative Medicines Initiative (IMI), the world’s largest public-private partnership in health care, has launched the first two projects under its antimicrobial resistance research program, New Drugs for Bad Bugs (ND4BB). The new projects, COMBACTE (Combating Bacterial Resistance in Europe) and TRANSLOCATION (Molecular basis of the bacterial cell wall permeability), are set to revitalize antibiotic development by promoting greater collaboration within the entire antibiotic development community, and by tackling key challenges to the development of new medicines.

More... »

$262M Pan-European drug discovery platform launched

Friday, February 8, 2013 10:48 AM

The European Lead Factory, a novel platform for innovative drug discovery, was launched Feb. 7 by an international consortium of 30 partners. The partnership, the first of its kind, is supported by the Innovative Medicines Initiative (IMI) and creates opportunities for the discovery of new medicines by providing public partners with an “industry-like” discovery platform to translate cutting-edge academic research into high-quality drug lead molecules on a scale and speed that was not possible previously.

More... »

IMI launches $319M 8th call for proposals

Tuesday, December 18, 2012 10:41 AM

The Innovative Medicines Initiative (IMI), the world’s largest public-private partnership in health, is launching its eighth call for proposals. With a total budget of $319 million ($188 million cash from IMI, plus a $131 million in-kind contribution from participating EFPIA companies), the projects resulting from this call will tackle some of the biggest challenges in health research.

More... »

Roche, IMI launch StemBANCC partnership for stem cells as research tools

Wednesday, December 5, 2012 02:03 PM

Switzerland-based Roche and the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients, have launched StemBANCC, a new academic–industry partnership that unites 10 pharmaceutical companies and 23 academic institutions.

More... »

10 pharmas form nonprofit TransCelerate to accelerate R&D of new medicines

Wednesday, September 19, 2012 02:46 PM

Ten biopharmaceutical companies have formed a non-profit organization, TransCelerate BioPharma, to accelerate the development of new medicines. Participants include Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech and Sanofi.

More... »

IMI tackles health research challenges with 7 new projects

Friday, June 8, 2012 12:45 PM

The Innovative Medicines Initiative (IMI), a public-private partnership in health R&D, has successfully launched its third wave of projects. The seven new projects, which have a combined total cost of $267 million and will run for five years, are taking on some of the biggest challenges in healthcare research.

More... »

Academic-industry collaboration seeks new drugs, treatments for autism

Monday, March 19, 2012 02:41 PM

An international consortium of scientists led by Roche, King's College London and Autism Speaks is collaborating on one of the largest ever academic-industry research projects, to find new methods for the development of drugs for autism spectrum disorder (ASD), which affects 1% of children worldwide.

More... »

IMI creates platform to discover novel medicines

Monday, March 12, 2012 02:04 PM

In an effort to speed up the discovery of new medicines, the Innovative Medicines Initiative (IMI) has created the European Lead Factory, a Europe-wide public-private partnership that combines the Joint European Compound Collection, a comprehensive collection of candidate drug molecules, with an industry-like screening center.

More... »